From empiricism to rational design: a personal perspective of the evolution of vaccine development

[1]  J. Jenks.  An Inquiry into the Causes and Effects of the Variolae Vaccinae , 2015 .

[2]  World Malaria Day 2014: invest in the future. Defeat malaria. , 2014, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[3]  P. Dormitzer,et al.  A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults , 2014, Science Translational Medicine.

[4]  Yuri Kotliarov,et al.  Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses , 2014, Cell.

[5]  Patrick G. Shaw,et al.  C9orf72 Nucleotide Repeat Structures Initiate Molecular Cascades of Disease , 2014, Nature.

[6]  Natalie K. Connors,et al.  Bioengineering virus‐like particles as vaccines , 2014, Biotechnology and bioengineering.

[7]  T. Odrljin,et al.  Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. , 2014, Vaccine.

[8]  Z. Bhutta,et al.  Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. , 2014, The Lancet. Infectious diseases.

[9]  Shuzhao Li,et al.  Vaccine Activation of the Nutrient Sensor GCN2 in Dendritic Cells Enhances Antigen Presentation , 2014, Science.

[10]  Sandra Romero-Steiner,et al.  Molecular signatures of antibody responses derived from a systems biological study of 5 human vaccines , 2013, Nature Immunology.

[11]  Shawn T. Brown,et al.  Contagious diseases in the United States from 1888 to the present. , 2013, The New England journal of medicine.

[12]  R. Janssen,et al.  Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. , 2013, Vaccine.

[13]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[14]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[15]  Mario Roederer,et al.  Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine , 2013, Science.

[16]  G. Plosker.  13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Infants, Children, and Adolescents , 2013, Pediatric Drugs.

[17]  S. Madhi,et al.  Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. , 2013, Vaccine.

[18]  Timothy B. Stockwell,et al.  Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics , 2013, Science Translational Medicine.

[19]  S. Geary,et al.  Prostate cancer vaccines , 2013, Oncoimmunology.

[20]  S. Black,et al.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) , 2013, Human vaccines & immunotherapeutics.

[21]  D. G. Gibson,et al.  Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice , 2013, Emerging Microbes & Infections.

[22]  C. Elias,et al.  Global Vaccine Action Plan 2011-2020. , 2013 .

[23]  Pandemics Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to , 2013 .

[24]  Kwaku Poku Asante,et al.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.

[25]  M. Ladjemi.  Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements , 2012, Front. Oncol..

[26]  Lucy A. Perrone,et al.  Adjuvant solution for pandemic influenza vaccine production , 2012, Proceedings of the National Academy of Sciences.

[27]  R. Rappuoli,et al.  Developing vaccines in the era of genomics: a decade of reverse vaccinology. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[29]  Rino Rappuoli,et al.  Influenza: Options to Improve Pandemic Preparation , 2012, Science.

[30]  J. Musser,et al.  Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus Case , 2012, Molecular & Cellular Proteomics.

[31]  D. Vaughn,et al.  Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion , 2012, Expert review of vaccines.

[32]  A. Didierlaurent,et al.  Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach , 2011, BioDrugs.

[33]  R. Rappuoli,et al.  A sweet T cell response , 2011, Nature Medicine.

[34]  T. Vesikari,et al.  Oil-in-water emulsion adjuvant with influenza vaccine in young children. , 2011, The New England journal of medicine.

[35]  R. Rappuoli,et al.  Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity , 2011, Science Translational Medicine.

[36]  A. Aderem,et al.  A 2020 vision for vaccines against HIV, tuberculosis and malaria , 2011, Nature.

[37]  D. Mehrotra,et al.  An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). , 2011, The Journal of infectious diseases.

[38]  Alessandro Sette,et al.  Reverse vaccinology: developing vaccines in the era of genomics. , 2010, Immunity.

[39]  Thomas H Segall-Shapiro,et al.  Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome , 2010, Science.

[40]  R. Rappuoli,et al.  New adjuvants for human vaccines. , 2010, Current opinion in immunology.

[41]  E. Tognotti.  The eradication of smallpox, a success story for modern medicine and public health: what lessons for the future? , 2010, Journal of infection in developing countries.

[42]  Rino Rappuoli,et al.  Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli , 2010, Proceedings of the National Academy of Sciences.

[43]  A MarioCalvo,et al.  Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .

[44]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[45]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[46]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[47]  G. Ireton,et al.  Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis1 , 2008, The Journal of Immunology.

[48]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[49]  Rino Rappuoli,et al.  Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.

[50]  R. Rappuoli,et al.  Molecular and cellular signatures of human vaccine adjuvants , 2008, Proceedings of the National Academy of Sciences.

[51]  M. Kalin,et al.  Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies , 2008, The Journal of experimental medicine.

[52]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[53]  S. Plotkin.  New rotavirus vaccines. , 2006, The Pediatric infectious disease journal.

[54]  M. Pichichero.  Meningococcal conjugate vaccines , 2005, Expert opinion on biological therapy.

[55]  G. Bensi,et al.  Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells. , 2005, Vaccine.

[56]  H. Tettelin,et al.  Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen , 2005, Science.

[57]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[58]  Sally Blower,et al.  An attempt at a new analysis of the mortality caused by smallpox and of the advantages of inoculation to prevent it y , 2004 .

[59]  G. Phillips,et al.  Invest in the future , 2003 .

[60]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[61]  Johannes Söllner,et al.  Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  L. Shaw,et al.  Safety of a new conjugate meningococcal C vaccine in infants , 2001, Archives of disease in childhood.

[63]  J. Mattick,et al.  Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. , 2001, Vaccine.

[64]  J. Shiloach,et al.  The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. , 2001, The New England journal of medicine.

[65]  D. Martin,et al.  Candidate Neisseria meningitidis NspA vaccine. , 2000, Journal of biotechnology.

[66]  T. Popović,et al.  Distribution of Neisseria meningitidisSerogroup B Serosubtypes and Serotypes Circulating in the United States , 2000, Journal of Clinical Microbiology.

[67]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[68]  S. Salzberg,et al.  Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. , 2000, Science.

[69]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[70]  R. Rappuoli.  Reverse vaccinology : Genomics , 2000 .

[71]  T. Popović,et al.  Distribution of Neisseria meningitidis Serogroup B Serosubtypes and Serotypes Circulating in the United States , 2000 .

[72]  J. Hay.  Vaccinia, Vaccination, Vaccinology: Jenner, Pasteur and Their Successors , 1997 .

[73]  E. Hewlett.  Pertussis: current concepts of pathogenesis and prevention. , 1997, The Pediatric infectious disease journal.

[74]  R. Rappuoli.  Rational design of vaccines , 1997, Nature Medicine.

[75]  D. Ala'aldeen.  Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. , 1996, Journal of medical microbiology.

[76]  D Greco,et al.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.

[77]  R. Fleischmann,et al.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.

[78]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[79]  R. Rappuoli,et al.  Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. , 1992, Vaccine.

[80]  I. Frazer,et al.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. , 1991, Virology.

[81]  E. Dahl-Hansen,et al.  Immunogenicity of yeast-derived hepatitis B vaccine from two different producers , 1990, Epidemiology and Infection.

[82]  L. Nencioni,et al.  Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.

[83]  F. Michon,et al.  Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. , 1989, Microbial pathogenesis.

[84]  E. Scolnick,et al.  Live attenuated varicella virus vaccine. Efficacy trial in healthy children. , 1984, The New England journal of medicine.

[85]  Y. Sato,et al.  DEVELOPMENT OF A PERTUSSIS COMPONENT VACCINE IN JAPAN , 1984, The Lancet.

[86]  B D Hall,et al.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast , 1982, Nature.

[87]  J. Needham.  China and the origins of immunology. , 1980, Eastern horizon.

[88]  A. Sutton,et al.  Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines. , 1980, Progress in clinical and biological research.

[89]  Y. Sato,et al.  Separation and characterization of two distinct hemagglutinins contained in purified leukocytosis-promoting factor from Bordetella pertussis. , 1976, Biochimica et biophysica acta.

[90]  Maurice R. Hilleman,et al.  Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B , 1976, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[91]  R. D. Reid,et al.  Prevention of pneumococcal pneumonia by vaccination. , 1976, Transactions of the Association of American Physicians.

[92]  C. Hall,et al.  Live attenuated influenza virus vaccine trial in children. , 1975, Pediatrics.

[93]  P. Anderson,et al.  Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b. , 1972, The Journal of clinical investigation.

[94]  S. Plotkin,et al.  Attenuation of RA 27-3 rubella virus in WI-38 human diploid cells. , 1969, American journal of diseases of children.

[95]  M. Artenstein,et al.  Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .

[96]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .

[97]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS : III. PREPARATION AND IMMUNOCHEMICAL PROPERTIES OF THE GROUP A, GROUP B, AND GROUP C MENINGOCOCCAL POLYSACCHARIDES , 1969 .

[98]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS , 1969, The Journal of experimental medicine.

[99]  M. Hilleman,et al.  Development and evaluation of the Moraten measles virus vaccine. , 1968, JAMA.

[100]  M. Hilleman,et al.  Live, attenuated mumps-virus vaccine. , 1968, The New England journal of medicine.

[101]  Edward Jenner,et al.  An inquiry into the causes and effects of the Variolæ vaccinæ, 1798 , 1966 .

[102]  S. Katz,et al.  Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination. , 1960, The New England journal of medicine.

[103]  R. Haggerty,et al.  Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine. , 1960, The New England journal of medicine.

[104]  A. Sabin,et al.  Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types. , 1954 .

[105]  B. L. Bennett,et al.  Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. , 1954, American journal of public health and the nation's health.

[106]  O. Avery,et al.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS , 1929, The Journal of experimental medicine.

[107]  O. Avery,et al.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS. , 1929 .

[108]  A. T. Glenny,et al.  Diphtheria Toxoid as an Immunising Agent. , 1923 .

[109]  Behring,et al.  Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren , 1890 .

[110]  이기수,et al.  II , 1856, My Karst and My City and Other Essays.

[111]  Thucydides,et al.  Θογκγδιδης : the History of the Peloponnesian War , 1847 .

[112]  Sandra Romero-Steiner,et al.  Molecular signatures of antibody responses derived from a systems biology study of five human vaccines , 2022 .